Heterodimeric antibodies that bind CD3 and tumor antigens
The present invention is directed to novel heterodimeric antibodies.
1. A heterodimeric antibody comprising:
a) a first monomer comprising an anti-CD3 scFv-linker-CH2-CH3, wherein CH2-CH3 is a first IgG Fc domain and said anti-CD3 scFv comprises a first variable heavy chain having the amino acid sequence of SEQ ID NO: 10, a first variable light chain having the amino acid sequence of SEQ ID NO: 14, and a scFv linker that attaches said first variable heavy chain with said first variable light chain;
b) a second monomer comprising a VH-CH1-hinge-CH2-CH3, wherein VH is a second variable heavy chain and CH2-CH3 is a second IgG Fc domain; and
c) a light chain comprising a second variable light chain.
2. A heterodimeric antibody according to claim 1 , wherein said first and second IgG Fc domains are variants of a human IgG Fc domain.
3. A heterodimeric antibody according to claim 1 wherein said first IgG Fc domain comprises amino acid substitutions S364K/E357Q and said second Fc domain comprises amino acid substitutions L368D/K370S.
4. A heterodimeric antibody according to claim 1 , wherein said second variant IgG Fc domain comprises amino acid substitutions N208D/Q295E/N384D/Q418E/N421D.
5. A heterodimeric antibody according to claim 1 , wherein said first and second IgG Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K.
6. A heterodimeric antibody according to claim 1 , wherein said linker is a charged linker.
7. A heterodimeric antibody according to claim 1 , wherein said anti-CD3 scFv comprises the amino acid sequence of SEQ ID NO: 18.
8. A heterodimeric antibody according to claim 1 , wherein said first IgG Fc domain comprises amino acid substitutions S364K/E357Q and said second Fc domain comprises amino acid substitutions L368D/K370S,
wherein said first and second IgG Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K,
wherein said first and second IgG Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K, and
wherein said second IgG Fc domain comprises amino acid substitutions N208D/Q295E/N384D/Q418E/N421D.
9. A heterodimeric antibody according to claim 1 , wherein said linker-CH2-CH3 of said first monomer has the amino acid sequence of SEQ ID NO: 472 and said CH1-hinge-CH2-CH3 of said second monomer has the amino acid sequence of SEQ ID NO: 471.
10. A heterodimeric antibody comprising:
a) a first monomer comprising a VH1-CH1-linker1-VH2-scFv linker-VL2-linker2-CH2-CH3,
wherein VH2-scFv linker-VL2 is an anti-CD3 scFV, linker 1 and linker 2 are a first linker and second linker, respectively, and CH2-CH3 is a first IgG Fc domain;
b) a second monomer comprising a VH1-CH1-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a second IgG Fc domain;
c) a common light chain comprising a first variable light domain (VL1); and
wherein said first variable heavy domain on said first monomer and said first variable light domain form a first binding domain, and said first variable heavy domain on said second monomer and said first variable light domain form a second binding domain, and
wherein said VH2 is a second variable heavy domain having the amino acid sequence of SEQ ID NO: 10 and said VL2 is a second variable light domain having the amino acid sequence of SEQ ID NO: 14.
11. A heterodimeric antibody according to claim 10 , wherein said first and second IgG Fc domains are variants of a human IgG Fc domain.
12. A heterodimeric antibody according to claim 10 , wherein said first IgG Fc domain comprises amino acid substitutions S364K/E357Q and said second IgG Fc domain comprises amino acid substitutions L368D/K370S.
13. A heterodimeric antibody according to claim 10 , wherein said second IgG Fc domain comprises amino acid substitutions N208D/Q295E/N384D/Q418E/N421D.
14. A heterodimeric antibody according to claim 10 , wherein said first and second IgG Fc domains comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K.
15. A heterodimeric antibody according to claim 10 , wherein said scFv linker is a charged linker.
16. A heterodimeric antibody according to claim 10 , wherein said first IgG Fc domain comprises amino acid substitutions S364K/E357Q and said second Fc domain comprises amino acid substitutions L368D/K370S,
wherein said first and second IgG Fc domains each comprise amino acid substitutions E233P/L234V/L235A/G236del/S267K, and
wherein said second IgG Fc domain comprises amino acid substitutions N208D/Q295E/N384D/Q418E/N421D.
17. A heterodimeric antibody according to claim 10 , wherein said anti-CD3 scFv comprises the amino acid sequence of SEQ ID NO: 18.
18. A nucleic acid composition comprising:
a) a first nucleic acid encoding said first monomer of claim 1 ;
b) a second nucleic acid encoding said second monomer of claim 1 ; and
c) a third nucleic acid encoding said light chain of claim 1 .
19. An expression vector composition comprising:
a) a first expression vector comprising a first nucleic acid encoding said first monomer of claim 1 ;
b) a second expression vector comprising a second nucleic acid encoding said second monomer of claim 1 ; and
c) a third expression vector comprising a third nucleic acid encoding said light chain of claim 1 .
20. A host cell comprising said expression vector composition of claim 19 .
21. A method of making a heterodimeric antibody comprising culturing the host cell of claim 20 under conditions wherein said heterodimeric antibody is expressed, and recovering said heterodimeric antibody.
22. A nucleic acid composition comprising:
a) a first nucleic acid encoding said first monomer of claim 10 ;
b) a second nucleic acid encoding said second monomer of claim 10 ; and
c) a third nucleic acid encoding said common light chain of claim 10 .
23. An expression vector composition comprising:
a) a first expression vector comprising a first nucleic acid encoding said first monomer of claim 10 ;
b) a second expression vector comprising a second nucleic acid encoding said second monomer of claim 10 ; and
c) a third expression vector comprising a third nucleic acid encoding said common light chain of claim 10 .
24. A host cell comprising said expression vector composition of claim 23 .
25. A method of making a heterodimeric antibody comprising culturing the host cell of claim 24 under conditions wherein said heterodimeric antibody is expressed, and recovering said heterodimeric antibody.